Latest filing published 12 Aug 2021 for Arcturus Therapeutics Holdings Inc., €34.3M.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Ultragenyx Pharmaceutical Inc.: trading record in brief
Ultragenyx Pharmaceutical Inc. is a declared insider of Arcturus Therapeutics Holdings Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 20 May 2020 to 11 August 2021, the count stands at 5 filings.
Sales make up the whole of the open-market record (4 sales, €103.8M). Other entries cover 1 option exercise. So far in 2021, the count stands at no purchases and 2 sales.
Most recently, on 12 August 2021, the filings show an open-market sale worth €2.9M in Arcturus Therapeutics Holdings Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Ultragenyx Pharmaceutical Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 725,000 shares@ US$55.44100.0% of flowCommon StockSEC:0001209191-21-051182:0
1 of 1 declaration
